Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TreoFC conditioning before haploidentical HSCT in older patients with AML or MDS
2021-004730-11Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan, fludarabine and cyclophosphamide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Medical University of Vienna. Primary endpoint: Overall survival. Started Jan 2022; status: terminated.
02
Drugs
treosulfanfludarabinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-004730-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004730-11.